Myriad Genetics in Active Talks with UnitedHealthcare to Keep Coverage of GeneSight

Dow Jones

2024-11-05

By Sabela Ojea

Myriad Genetics said it is in talks with UnitedHealthcare to ensure that enrollees continue to have access to its GeneSight mental health medication test after the insurer changed its coverage policy.

The genetic testing and precision medicine company on Monday said it strongly disagrees with UnitedHealthcare's inclusion of GeneSight after it announced it would no longer cover multi-panel genetic tests for behavioral-health diagnoses.

"Myriad is actively engaging with UnitedHealthcare to discuss the large body of evidence for Myriad's proprietary and clinically differentiated mental health medication test," the company said.

Myriad Genetics doesn't believe that the updated policy affects coverage of GeneSight by UnitedHealthcare under Medicare Advantage and managed Medicaid plans, it added.

The company is expected to post third-quarter results after the market close Thursday.

Myriad Genetics shares were down 4.9% at $16.93 in morning trading. The stock has dropped 34% over the past three months.

Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix

(END) Dow Jones Newswires

November 04, 2024 11:38 ET (16:38 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2481536976"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2481536976\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2481536976?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-05 00:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2481536976","market":"sg","top_or_hot":-1,"title":"Myriad Genetics in Active Talks with UnitedHealthcare to Keep Coverage of GeneSight","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Sabela Ojea \n</p>\n<pre>\n \n</pre>\n<p>\n  Myriad Genetics said it is in talks with UnitedHealthcare to ensure that enrollees continue to have access to its GeneSight mental health medication test after the insurer changed its coverage policy. \n</p>\n<p>\n  The genetic testing and precision medicine company on Monday said it strongly disagrees with UnitedHealthcare's inclusion of GeneSight after it announced it would no longer cover multi-panel genetic tests for behavioral-health diagnoses. \n</p>\n<p>\n  \"Myriad is actively engaging with UnitedHealthcare to discuss the large body of evidence for Myriad's proprietary and clinically differentiated mental health medication test,\" the company said. \n</p>\n<p>\n  Myriad Genetics doesn't believe that the updated policy affects coverage of GeneSight by UnitedHealthcare under Medicare Advantage and managed Medicaid plans, it added. \n</p>\n<p>\n  The company is expected to post third-quarter results after the market close Thursday. \n</p>\n<p>\n  Myriad Genetics shares were down 4.9% at $16.93 in morning trading. The stock has dropped 34% over the past three months. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 04, 2024 11:38 ET (16:38 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Myriad Genetics in Active Talks with UnitedHealthcare to Keep Coverage of GeneSight</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMyriad Genetics in Active Talks with UnitedHealthcare to Keep Coverage of GeneSight\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2024-11-05 00:38</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Sabela Ojea \n</p>\n<pre>\n \n</pre>\n<p>\n  Myriad Genetics said it is in talks with UnitedHealthcare to ensure that enrollees continue to have access to its GeneSight mental health medication test after the insurer changed its coverage policy. \n</p>\n<p>\n  The genetic testing and precision medicine company on Monday said it strongly disagrees with UnitedHealthcare's inclusion of GeneSight after it announced it would no longer cover multi-panel genetic tests for behavioral-health diagnoses. \n</p>\n<p>\n  \"Myriad is actively engaging with UnitedHealthcare to discuss the large body of evidence for Myriad's proprietary and clinically differentiated mental health medication test,\" the company said. \n</p>\n<p>\n  Myriad Genetics doesn't believe that the updated policy affects coverage of GeneSight by UnitedHealthcare under Medicare Advantage and managed Medicaid plans, it added. \n</p>\n<p>\n  The company is expected to post third-quarter results after the market close Thursday. \n</p>\n<p>\n  Myriad Genetics shares were down 4.9% at $16.93 in morning trading. The stock has dropped 34% over the past three months. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 04, 2024 11:38 ET (16:38 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03650","symbol_name":"KEEP","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2481536976","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2481536976","pubTimestamp":1730738280,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Myriad Genetics said it is in talks with UnitedHealthcare to ensure that enrollees continue to have access to its GeneSight mental health medication test after the insurer changed its coverage policy.The genetic testing and precision medicine company on Monday said it strongly disagrees with UnitedHealthcare's inclusion of GeneSight after it announced it would no longer cover multi-panel genetic tests for behavioral-health diagnoses.\"Myriad is actively engaging with UnitedHealthcare to discuss the large body of evidence for Myriad's proprietary and clinically differentiated mental health medication test,\" the company said.Myriad Genetics doesn't believe that the updated policy affects coverage of GeneSight by UnitedHealthcare under Medicare Advantage and managed Medicaid plans, it added.The company is expected to post third-quarter results after the market close Thursday.Myriad Genetics shares were down 4.9% at $16.93 in morning trading. The stock has dropped 34% over the past three mo","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03650":"KEEP","BK4139":"生物科技","MYGN":"万基遗传","BK1215":"特殊消费者服务"},"translate_title":"Myriad Genetics正在与UnitedHealthcare积极谈判，以保持GeneSight的覆盖范围","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03650":1,"MYGN":1},"content_text":"By Sabela Ojea \n\n\n \n\n\n  Myriad Genetics said it is in talks with UnitedHealthcare to ensure that enrollees continue to have access to its GeneSight mental health medication test after the insurer changed its coverage policy. \n\n\n  The genetic testing and precision medicine company on Monday said it strongly disagrees with UnitedHealthcare's inclusion of GeneSight after it announced it would no longer cover multi-panel genetic tests for behavioral-health diagnoses. \n\n\n  \"Myriad is actively engaging with UnitedHealthcare to discuss the large body of evidence for Myriad's proprietary and clinically differentiated mental health medication test,\" the company said. \n\n\n  Myriad Genetics doesn't believe that the updated policy affects coverage of GeneSight by UnitedHealthcare under Medicare Advantage and managed Medicaid plans, it added. \n\n\n  The company is expected to post third-quarter results after the market close Thursday. \n\n\n  Myriad Genetics shares were down 4.9% at $16.93 in morning trading. The stock has dropped 34% over the past three months. \n\n\n \n\n\n  Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 04, 2024 11:38 ET (16:38 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"}}}